Dr. Matthew Mei, MD
Claim this profileCity of Hope Medical Center
Expert in Cancer
Studies Hodgkin's Lymphoma
11 reported clinical trials
20 drugs studied
Area of expertise
1Cancer
Global LeaderCD30 positive
MYC positive
BCL2 positive
2Hodgkin's Lymphoma
CD30 positive
MYC positive
BCL2 positive
Affiliated Hospitals
Clinical Trials Matthew Mei, MD is currently running
Oral Azacitidine + R-miniCHOP
for Diffuse Large B-Cell Lymphoma
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-miniCHOP\]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as oral azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.
Recruiting1 award Phase 2 & 314 criteria
Tafasitamab + Zanubrutinib
for Chronic Lymphocytic Leukemia
This phase II trial tests how well tafasitamab and zanubrutinib works in treating patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein that signals cancer cells to multiply. This may stop the growth and spread of cancer cells. Giving tafasitamab and zanubrutinib in combination may kill more cancer cells in patients with CLL/SLL than giving either treatment alone.
Recruiting1 award Phase 2
More about Matthew Mei, MD
Clinical Trial Related12 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Matthew Mei, MD has experience with
- Nivolumab
- CD30.CAR-T
- CC-486
- Mosunetuzumab
- Polatuzumab Vedotin
- Tafasitamab
Breakdown of trials Matthew Mei, MD has run
Cancer
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Follicular Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Mei, MD specialize in?
Matthew Mei, MD focuses on Cancer and Hodgkin's Lymphoma. In particular, much of their work with Cancer has involved CD30 positive patients, or patients who are MYC positive.
Is Matthew Mei, MD currently recruiting for clinical trials?
Yes, Matthew Mei, MD is currently recruiting for 5 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Matthew Mei, MD has studied deeply?
Yes, Matthew Mei, MD has studied treatments such as Nivolumab, CD30.CAR-T, CC-486.
What is the best way to schedule an appointment with Matthew Mei, MD?
Apply for one of the trials that Matthew Mei, MD is conducting.
What is the office address of Matthew Mei, MD?
The office of Matthew Mei, MD is located at: City of Hope Medical Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.